Finland· FI-REL-REL29704
Extavia
A interferon beta-1b product containing interferon beta 1b, registered in Finland by Novartis Europharm Limited. The same ATC class is registered in 14 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Interferon beta-1b is registered in 14 of 19 countries.
Countries holding a registration under ATC L03AB08 (interferon beta-1b), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 9 of them publish a price we can compare per daily dose
Interferon beta-1b · ATC L03AB08
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
The record
At a glance
Fimea (Finland)- Active substance
- Interferon beta 1b
- Manufacturer
- Novartis Europharm Limited
- Country
- Finland (FI)
- ATC code
- L03AB08
- ATC class
- Interferon beta-1b
- Defined daily dose
- 4 MIO, E
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
347 interactions on record for interferon beta-1b.
Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Interferon beta-1b · interactions on record
347 records
- 15 severe
- 332 moderate
Most severe, free to view
- MipomersenC10AX11severe
- LomitapideC10AX12severe
- ZidovudineJ05AF01severe
- ClotrimazoleA01AB18moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Interferon beta-1b in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaBETAFERONBayer AG, Leverkusen
- SpainBETAFERON 250 MICROGRAMOS/ML POLVO Y DISOLVENTE PARA SOLUCION INYECTABLEBayer Ag
- United KingdomBetaferon 300microgram powder and solvent for solution for injection vialsOriginalis B.V.
- BelgiumBetaferon 0.25 mg/mlBayer
- FranceBETAFERON 250 microgrammes/ml, poudre et solvant pour solution injectableBAYER AG (ALLEMAGNE)
- PolandBetaferonBayer AG
- NetherlandsBetaferon, poeder en oplosmiddel voor oplossing voor injectieBayer AG
- NorwayBetaferonBayer AG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Betaferon
- Liechtenstein · Betaferon
- Norway · Betaferon
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e921e581-12e1-405a-bc65-e9a3972d28d6 GET /v1/drugs/e921e581-12e1-405a-bc65-e9a3972d28d6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": "4",
"form": "injektiokuiva-aine ja liuotin, liuosta varten",
"route": "Ihon alle",
"ddd_unit": "MU",
"strength": "250 mikrog/ml",
"atc_label": "interferoni beeta-1b",
"ma_number": null,
"auth_status": "Myyntilupa peruuntunut",
"eu_ma_number": "EU/1/08/454/008-014",
"fimea_rel_id": "REL29704",
"authorised_at": "2008-05-20"
}See everything about interferon beta-1b.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.